US2020282029A1PendingUtilityA1

Methods for treating osteoarthritis pain

Assignee: ALLERGAN INCPriority: Sep 12, 2014Filed: Jan 17, 2020Published: Sep 10, 2020
Est. expirySep 12, 2034(~8.1 yrs left)· nominal 20-yr term from priority
A61K 38/4893A61P 29/02A61P 19/02A61P 25/04A61K 9/0019
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for alleviating osteoarthritis-associated symptoms by selecting a treatment-eligible patient and local administration of a clostridial derivative, such as a botulinum toxin, to an osteoarthritis-affected site are disclosed herein.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method for treating or alleviating osteoarthritis (OA)-associated pain in a patient in need thereof, the method comprising locally administering a therapeutically effective amount of a clostridial derivative to an osteoarthritis-affected site of the OA patient, thereby treating or alleviating the osteoarthritis-associated pain in the patient,
 wherein the therapeutically effective amount is from about 200 units to about 800 units, and wherein the clostridial derivative is a botulinum toxin type A.   
     
     
         2 . The method of  claim 1 , wherein the osteoarthritis-affected site is selected from the group consisting of a knee joint, a hip joint, a hand joint, a shoulder joint, an ankle joint, a foot joint, an elbow joint, a wrist joint, a sacroiliac joint, a spine joint, and combinations thereof. 
     
     
         3 . The method of  claim 1 , wherein the administering is by intra-articular injection into a joint space. 
     
     
         4 . The method of  claim 1 , wherein the clostridial derivative is onabotulinumtoxinA. 
     
     
         5 . The method of  claim 4 , wherein the therapeutically effective amount ranges from about 300 to about 500 units of onabotulinumtoxinA. 
     
     
         6 . The method of  claim 5 , wherein the therapeutically effective amount is about 400 units. 
     
     
         7 . The method of  claim 1 , wherein the clostridial derivative is incobotulinumtoxinA. 
     
     
         8 . The method of  claim 7 , wherein the therapeutically effective amount ranges from about 300 to about 500 units of incobotulinumtoxinA. 
     
     
         9 . The method of  claim 8 , wherein the therapeutically effective amount is about 400 units. 
     
     
         10 . The method of  claim 1 , wherein the patient's pain is categorized as nociceptive.

Join the waitlist — get patent alerts

Track US2020282029A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.